Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07365839 · ClinicalTrials.gov registry record · Phase 1
Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma
A Phase 1 study, sponsored by Virginia Commonwealth University.
- Not yet
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT07365839 is a Phase 1 study that has not yet begun recruiting, run by Virginia Commonwealth University. The registered enrollment target is 20 participants.
The verdict
NCT07365839, a Phase 1 study, has not yet begun recruiting, sponsored by Virginia Commonwealth University.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
Randomized, 2-arm, non-comparative, pilot study assessing the efficacy of cemiplimab with or without fianlimab after treatment with yttrium-90 (Y90).
Interventions
- DRUG Arm 1 cemiplimab
- DRUG Arm 2 cemiplimab and fianlimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-07-01 |
| Est. Completion | 2035-02-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07365839
The ClinicalTrials.gov registry entry for NCT07365839 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Arm 1 cemiplimab is the first listed.
NCT07365839 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07365839 about?
NCT07365839 is a clinical study titled "Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma". Randomized, 2-arm, non-comparative, pilot study assessing the efficacy of cemiplimab with or without fianlimab after treatment with yttrium-90 (Y90).
What is the current status of trial NCT07365839?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2026-07-01. Estimated completion is 2035-02-28.
What interventions are being tested in trial NCT07365839?
The interventions under investigation include: Arm 1 cemiplimab (DRUG), Arm 2 cemiplimab and fianlimab (DRUG).
Who is sponsoring clinical trial NCT07365839?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.